Annual Drug Patent Expirations for BYDUREON+PEN
Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-nine patents protecting this drug.
This drug has four hundred and sixty-three patent family members in forty-eight countries.
The generic ingredient in BYDUREON PEN is exenatide synthetic. One supplier is listed for this compound. Additional details are available on the exenatide synthetic profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
